![Yong Ben](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 86 138 $ in data 31/05/2026
Attualmente, Yong Ben ricopre la posizione di Chief Medical Officer-Immuno & Oncology Department presso BeiGene Ltd. Il Dr. Ben ha ricevuto un dottorato dalla Norman Bethune Medical University e un MBA dalla University of California San Diego.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 19/05/2026 | 7.583 ( 0,04% ) | 59 982 $ | 31/05/2026 | |
0% | 20/04/2026 | 2.916 ( 0% ) | 26 157 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Direttore/Membro del Consiglio | 01/03/2023 |
Eight Roads Capital Advisors (CHINA)
 Eight Roads Capital Advisors (CHINA) Investment ManagersFinance Functions as an alternative investment manager | Investitore di Private Equity | 01/08/2022 |
| Società | Posizione | Fine |
|---|---|---|
| BEIGENE LTD | Direttore Tecnico/Scientifico/R&S | - |
| BIOATLA, INC. | Corporate Officer/Principal | 01/02/2019 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 6 |
|---|---|
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Norman Bethune Medical University
 Norman Bethune Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioAtla, Inc.
 BioAtla, Inc. BiotechnologyHealth Technology Develops novel monoclonal antibody and protein therapeutic products | Health Technology |
Corbus Pharmaceuticals Holdings, Inc.
 Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
BeiGene Ltd.
 BeiGene Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Eight Roads Capital Advisors (CHINA)
Eight Roads Capital Advisors (CHINA) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
